STTK - Shattuck Labs, Inc. Analyst Forecast Prices
Shattuck Labs, Inc. (STTK) relies on external financing as it remains in the testing phase of its immune therapies. A team of leading oncologists is working to save lives, utilizing generous research budgets. Growth prospects depend on new partnerships and phase II trials, with the metric standing at 16.36. The market price visualization on GURU.Markets demonstrates the price action of this biopharmaceutical asset.
Analytical breakdowns for Shattuck Labs, Inc. (STTK)
- price and consensus price forecast:
- market capitalization statistics:
- book capitalization information:
- business debt structure and liquidity details:
Aggregate Debt to Equity Shattuck Labs, Inc.|STTK - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital shattucklabs.com|STTK - Company Aggregate Debts|Debts to Book Capitalization Shattuck Therapeutics|STTK - Company Long-Term Debt|Company Short-Term Loans and Borrowings Shattuck Labs|Quick Liquidity Indicator shattucklabs.com
- earnings and market ratios statistics:
STTK - Net Profit|Projected Future Earnings Shattuck Labs, Inc.|STTK - Price to Earnings Ratio|Future Price to Earnings Multiple shattucklabs.com|STTK - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Shattuck Therapeutics|STTK - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Shattuck Labs|STTK - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months shattucklabs.com|STTK - Net earnings per share growth this year|Earnings growth forecast for next year Shattuck Labs, Inc.
General company analysis:STTK Shattuck Labs Inc
To isolate the fundamental stability of Shattuck Labs, Inc. (STTK) from market noise, the average target share price from leading investment houses is used, which currently stands at 16.36. By analyzing the history of analyst targets, an investor determines the convergence point of the price with the forecast, which is critically important for Shattuck Labs, Inc. (STTK) amid fierce competition with biotech startups and global pharma behemoths for leadership in immuno-oncology.
Competitors of Shattuck Labs, Inc.
Analyst Median Target argenx.com|BioNTech - Consensus Target|Analyst Forecast Prices ABVX (Abivax SA)|ADMA: Consensus Target|Protagonist Corp - Analyst Forecast Prices|Immunovant, Inc. (IMVT) - Price Target Chart|kiniksa.com (KNSA) - Analyst Consensus Forecast|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|JBIO - Price Target Chart|Analyst Median Target Aclaris Therapeutics, Inc ACRS|KYTX: Analyst Consensus Forecast|tizianalifesciences.com - Fair Value Consensus|CABA (Cabaletta Bio) - Analyst Consensus Forecast|Analyst Consensus Forecast Ventyx Biosciences Inc.|Consensus Target THTX (Theratechnologies Inc)|Analyst Forecast Prices AVTX|Eledon Pharmaceuticals - Consensus Target|Analyst Forecast Prices AGEN (agenusbio.com)|CLYM: Consensus Target|ZURA - Analyst Consensus Forecast|ATYR: Analyst Consensus Forecast|Consensus Target Adagene Inc.|Price Target Chart ImageneBio|Analyst Consensus Forecast Equillium Bio|Consensus Target CNTB (Connect Biopharma)|IMUX (immunic-therapeutics.com) - Fair Value Consensus|Price Target Chart Atara Bio ATRA|InflaRx NV - Price Target Chart|X4 Pharmaceuticals - Analyst Consensus Forecast|ACET - Analyst Consensus Forecast|CELU: Analyst Consensus Forecast|INMB (INmune Bio Inc) - Price Target Chart|Price Target Chart Barinthus Bio|Kezar Life Sciences Inc (KZR) - Analyst Median Target|Consensus Target SABS (SAB Biotherapeutics)|AKTX (akaritx.com) - Fair Value Consensus|Analyst Consensus Forecast ENLV (Enlivex Therapeutics Ltd.)|Analyst Median Target Q32 Bio Inc (QTTB)|GOVX - Price Target Chart|EDSA (Edesa Biotech Corp) - Broker Consensus Forecast|IBIO: Analyst Consensus Forecast|Consensus Target Carisma Therapeutics Inc.|Consensus Target XTLB|Bolt Bio (BOLT) - Analyst Median Target|Price Target Chart HCW Biologics Inc. (HCWB)|Analyst Median Target aptevotherapeutics.com|AIM ImmunoTech - Consensus Target|Analyst Forecast Prices ADTX (Aditxt Inc.)|GRI: Consensus Target|XORTX Therapeutics Inc - Analyst Forecast Prices|ReShape Lifesciences (HIND) - Price Target Chart|Revelation Biosciences Corp (REVB) - Analyst Consensus Forecast|Price Target Chart Indaptus Therapeutics|scinai.com - Forecast Levels Chart|Analyst Consensus Forecast CALI|AFMD (affimed.com) - Fair Value Consensus|Analyst Consensus Forecast ALLK (Allakos)|Analyst Consensus Forecast HOOKIPA Pharma, Inc. HOOK|IGMS - Price Target Chart|Fair Value Consensus ITOS (iteostherapeutics.com)|Ocean Biomedical (OCEA) - Price Target Chart|Consensus Target TC BioPharm (Holdings) Plc|THRD (Third Harmonic Bio, Inc) - Analyst Consensus Forecast
